Sermorelin + MK-677 (Ibutamoren) Stack: Complete Protocol

Why Stack Sermorelin With MK-677 at All?

The rationale is receptor-level complementarity. Sermorelin stimulates the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, which drives GH synthesis and release. MK-677 activates the ghrelin receptor (GHSR-1a), a structurally distinct G-protein-coupled receptor that amplifies GH-pulse amplitude through a different intracellular cascade. Because neither agent saturates both pathways alone, combining them may produce additive, or in some conditions supra-additive, GH secretion.

Animal data are consistent with this idea. A 1997 study in the Journal of Clinical Endocrinology and Metabolism confirmed that co-administration of a GHRH peptide with a ghrelin-receptor agonist produced greater GH release than either agent alone in healthy men, supporting the two-pathway model [1]. MK-677 itself, in a 24-month placebo-controlled trial (N=65 elderly subjects), significantly increased IGF-1 levels and lean body mass without changing fat mass at 25 mg/day [2].

No published RCT has tested Sermorelin plus MK-677 together. This article synthesizes single-agent RCT data, mechanistic studies, and clinician-reported protocols. Evidence gaps are noted explicitly throughout.

How Each Agent Works

Sermorelin: Restoring the GHRH Pulse

Sermorelin acetate is a synthetic version of the first 29 amino acids of endogenous GHRH. It binds GHRHR on pituitary somatotrophs and triggers a cAMP-dependent release of GH within minutes. Because it mimics a physiological signal, GH release remains subject to normal hypothalamic feedback, including somatostatin suppression. This feedback preservation is why Sermorelin is considered lower-risk for runaway IGF-1 elevation compared with exogenous recombinant human GH (rhGH).

The FDA approved Sermorelin acetate for injection (brand: Geref) for diagnosis and treatment of GH deficiency in pediatric patients. That approval was withdrawn in 2008 for commercial, not safety, reasons [3]. Off-label adult use in compounded form is now the dominant clinical context.

MK-677: The Oral Ghrelin Mimetic

MK-677 (ibutamoren mesylate) is not technically a peptide. It is a small-molecule, orally bioavailable ghrelin-receptor agonist developed by Merck in the 1990s. It raises GH by mimicking ghrelin at GHSR-1a, which both amplifies GH-pulse amplitude and reduces somatostatin tone. The oral route makes it far more convenient than injected secretagogues.

A Phase II trial published in the Journal of Clinical Endocrinology and Metabolism (N=24 GH-deficient adults) showed MK-677 25 mg daily for 4 months raised IGF-1 by roughly 40% from baseline and improved nitrogen balance, a proxy for anabolism [4]. MK-677 also crosses the blood-brain barrier and increases ghrelin signaling centrally, which explains its consistent side effect of appetite stimulation.

The Two-Pathway Model in Practice

When Sermorelin fires the GHRHR and MK-677 fires GHSR-1a simultaneously, both signals converge on the somatotroph at the same time. The result is a GH pulse that is broader in amplitude than either agent could produce alone. Think of Sermorelin as the ignition and MK-677 as a turbocharger running on a separate fuel line.

HealthRX clinicians use a tiered approach to this stack:

• Tier 1 (conservative): Sermorelin 200 mcg at bedtime + MK-677 10 mg at bedtime. Goal: baseline IGF-1 optimization with minimal side-effect burden. Suitable for adults 35 to 50 with low-normal IGF-1.
• Tier 2 (standard): Sermorelin 250 to 300 mcg at bedtime + MK-677 15 to 20 mg at bedtime. Goal: meaningful body-composition shift over a 3 to 6 month cycle.
• Tier 3 (advanced, physician-supervised only): Sermorelin 300 mcg at bedtime + MK-677 25 mg at bedtime. Goal: near-maximal secretagogue stimulus. Requires baseline and 6-week IGF-1 checks, fasting glucose, and HbA1c.

Dosing Protocol in Detail

Sermorelin Dosing

The compounded Sermorelin formulation used in adults is typically reconstituted with bacteriostatic water and administered subcutaneously in the periumbilical region. Standard adult doses in clinical practice range from 200 to 300 mcg per injection. Timing matters: GH secretion follows a circadian rhythm with the largest endogenous pulse occurring 60 to 90 minutes after sleep onset, so a bedtime injection aligns the drug effect with that natural peak [5].

Sermorelin is typically prescribed as a 5-days-on, 2-days-off schedule (weekdays only) to limit tachyphylaxis, though some protocols use nightly dosing continuously. Cycle length in most clinical reports is 3 to 6 months, followed by a 4- to 8-week washout.

MK-677 Dosing

MK-677 is taken orally, usually as a capsule or tablet. The dose range studied in RCTs is 10 to 50 mg daily; 25 mg/day is the most commonly cited effective dose [2]. Because MK-677 has a half-life of approximately 24 hours, once-daily dosing is sufficient. Taking it at night minimizes daytime hunger and aligns peak GH secretion with sleep.

Starting at 10 mg for the first 2 weeks allows assessment of individual tolerance before titrating to 15 to 25 mg. Users who experience significant water retention or appetite overstimulation often find that dropping to 10 mg eliminates the problem while preserving most of the IGF-1 benefit.

Timing the Two Agents Together

Both agents are taken at the same time, at bedtime, to synchronize their effects on the nocturnal GH surge. Sermorelin is injected first (subcutaneous), then MK-677 is taken orally. There is no pharmacokinetic reason to separate them. Food should be avoided for at least 90 minutes before dosing both agents, since elevated insulin blunts GH release [6].

Cycle Structure

A practical cycle for a 40-year-old male with low-normal IGF-1 (age-adjusted range 75 to 200 ng/mL) might look like this:

| Phase | Duration | Sermorelin | MK-677 | |---|---|---|---| | Ramp | Weeks 1 to 2 | 200 mcg nightly | 10 mg nightly | | Maintenance | Weeks 3 to 16 | 250 to 300 mcg nightly | 15 to 25 mg nightly | | Taper/washout | Weeks 17 to 20 | Discontinue | Discontinue | | Re-evaluate | Week 21 | Check IGF-1, glucose, HbA1c | Re-assess for next cycle |

Expected Outcomes and Evidence

IGF-1 and Body Composition

In the key 2-year MK-677 trial (N=65), subjects receiving 25 mg/day showed a sustained increase in IGF-1 of approximately 60% above baseline and a lean mass gain of roughly 1.6 kg versus placebo at 12 months [2]. Sermorelin's individual-agent data are less abundant in adults, but a mechanistic study in healthy men showed significant GH pulse amplification within 4 weeks of nightly GHRH-analogue use [7].

When both agents are stacked, IGF-1 increases may be larger than with either agent alone, but no trial has measured the magnitude of this combined effect. Clinician-reported outcomes suggest an IGF-1 rise of 40 to 80% from baseline over 12 weeks at standard doses, though this figure comes from clinical observation, not controlled data.

Sleep Quality

MK-677 reliably increases slow-wave (deep) sleep. In a crossover study of healthy young and older men, MK-677 25 mg increased REM sleep and slow-wave sleep duration significantly compared with placebo [8]. Sermorelin also appears to improve sleep architecture by augmenting nocturnal GH pulses, though direct RCT data in adults are sparse.

Bone Density

The 2-year MK-677 trial showed a trend toward improved bone mineral density, consistent with IGF-1's known role in osteoblast stimulation [2]. Sermorelin's effects on bone in adults have not been studied in dedicated RCTs.

What This Stack Cannot Do

This stack is not a substitute for medically diagnosed GH deficiency treatment. Adults with confirmed GH deficiency (peak GH <5 ng/mL on stimulation testing per Endocrine Society guidelines) may require recombinant human GH, not a secretagogue stack [9]. Secretagogues depend on a functioning pituitary; patients with hypopituitarism from pituitary adenoma, radiation, or surgery may see little response.

Side Effects and Risk Profile

Metabolic: Glucose and Insulin Sensitivity

The most clinically meaningful risk is glucose dysregulation. MK-677's ghrelin-mimetic action increases cortisol and can impair insulin sensitivity. In the 2-year trial, fasting blood glucose rose modestly (roughly 0.3 mmol/L above placebo) and one subject developed frank hyperglycemia requiring discontinuation [2]. Sermorelin carries a similar, though likely smaller, metabolic signal because high IGF-1 can suppress insulin-like metabolic pathways.

Monitoring fasting glucose and HbA1c every 6 to 8 weeks is not optional for anyone using this stack. Pre-diabetic patients (HbA1c 5.7 to 6.4%) should use the lowest effective dose or avoid the stack entirely.

Water Retention and Joint Discomfort

Both agents increase GH, and supraphysiological GH promotes sodium and water retention via renal tubular mechanisms. Mild peripheral edema and joint aching (particularly in the wrists and ankles) are common early in a cycle. These effects usually resolve after 2 to 4 weeks as the body adapts, or they resolve promptly upon dose reduction.

Appetite Stimulation

MK-677 reliably increases appetite, consistent with ghrelin's orexigenic role. For patients using this stack for body recomposition, increased appetite can undermine caloric targets. Scheduling dosing at bedtime reduces daytime hunger but does not eliminate the effect entirely.

Prolactin and Cortisol

Ghrelin-receptor agonists mildly raise cortisol and prolactin. In most trial populations, these elevations remain within normal range, but baseline and follow-up measurement is prudent for any patient with a history of pituitary pathology [4].

Cardiovascular Signals

The 2019 PROMISE trial examined MK-677's cardiovascular safety in 207 elderly hip-fracture patients and was halted early due to an increase in congestive heart failure events in the MK-677 arm [10]. While most clinicians believe this finding reflects fluid retention in a frail elderly population rather than a direct cardiotoxic effect, it warrants caution in patients with reduced ejection fraction or established heart failure.

Who Is (and Is Not) a Candidate

Reasonable Candidates

• Adults 35 to 65 with low-normal age-adjusted IGF-1 (typically <120 ng/mL in men over 40, <100 ng/mL in women over 40)
• Patients seeking improved sleep quality, lean mass maintenance, or recovery optimization
• Those who have already optimized nutrition, resistance training, and sleep hygiene without satisfactory results
• Patients with no history of malignancy, uncontrolled diabetes, or cardiac dysfunction

Contraindications

The Endocrine Society's 2011 clinical practice guideline on GH use states: "We recommend against GH treatment for patients with active malignancy" [9]. This recommendation logically extends to GH-stimulating secretagogue stacks. Active or recent cancer, untreated sleep apnea, uncontrolled type 2 diabetes, pregnancy, and known hypersensitivity to either agent are absolute contraindications.

Patients under 25 years old should not use this stack. Endogenous GH secretion is maximal during adolescence and early adulthood; adding secretagogue stimulus offers no benefit and may prematurely suppress the hypothalamic-pituitary axis.

Monitoring Protocol

Consistent monitoring is the difference between safe use and guesswork. The HealthRX standard monitoring panel for this stack:

| Timepoint | Tests | |---|---| | Baseline (before starting) | IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, fasting lipids, prolactin, cortisol (AM), TSH | | Week 6 | IGF-1, fasting glucose, HbA1c | | Week 12 (end of cycle or mid-cycle) | Full panel repeat | | 4 weeks after washout | IGF-1, fasting glucose |

Target IGF-1 during the stack: upper third of the age-adjusted reference range, not above range. The Endocrine Society defines an IGF-1 above the age-adjusted normal range as a signal to reduce GH-stimulating therapy [9].

Drug Interactions and Concurrent Medications

Sermorelin and MK-677 are not known to inhibit CYP450 enzymes at clinical doses, so conventional drug-drug interactions are limited. However, three scenarios deserve attention:

1. Insulin or oral hypoglycemics. MK-677's glucose-raising effect may require upward titration of diabetes medications. Close glucose monitoring is mandatory.
2. Glucocorticoids (e.g., prednisone). Exogenous corticosteroids blunt GH secretion and may reduce stack efficacy. The combination also stacks metabolic risk.
3. Thyroid hormone replacement. GH and IGF-1 accelerate conversion of T4 to T3. Patients on levothyroxine may find that IGF-1 elevation shifts their thyroid status; re-check TSH at the 12-week mark.

Regulatory Status and Compounding Considerations

MK-677 is not FDA-approved for any indication. It is classified as an investigational drug and is not a scheduled substance in the United States as of the date of this article's last review. Sermorelin is available in FDA-approved form (Geref, now discontinued commercially) and as a compounded preparation from 503A or 503B pharmacies.

In March 2024, the FDA proposed adding Sermorelin to a list of drugs that cannot be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, citing concerns about clinical need and safety standards. Patients should verify the current regulatory status with their prescribing physician before starting a compounded Sermorelin protocol, as the field is evolving [3].

MK-677 purchased outside a clinical context from research-chemical suppliers carries no quality assurance. Purity, dose accuracy, and sterility cannot be assumed.

Practical Lifestyle Considerations

The stack works best when layered on top of established lifestyle foundations, not used as a replacement for them.

• Resistance training. IGF-1 drives skeletal muscle protein synthesis most effectively when mechanical stimulus is present. Three to four sessions per week of progressive resistance training amplifies body-composition outcomes.
• Protein intake. Aim for 1.6 to 2.2 g of protein per kilogram of bodyweight per day, consistent with the International Society of Sports Nutrition position stand [11].
• Sleep hygiene. Both agents amplify nocturnal GH release, so protecting sleep duration (7 to 9 hours) and reducing sleep fragmentation directly increases protocol efficacy.
• Alcohol. Alcohol suppresses GH secretion acutely. Even moderate alcohol intake within 3 hours of the bedtime dose may blunt the response.